← Back to Search

Virus Therapy

Yellow Fever Vaccine for Yellow Fever Vaccination Reaction

Phase 4
Waitlist Available
Led By Phillip R Pittman, M.D., M.P.H.
Research Sponsored by US Army Medical Research Institute of Infectious Diseases
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to one year following vaccination.
Awards & highlights

Study Summary

This trial is testing whether a lower dose of yellow fever vaccine is just as effective as the standard dose.

Eligible Conditions
  • Yellow Fever Vaccination Reaction

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to one year following vaccination.
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to one year following vaccination. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Adverse Events
Antibodies, Blocking
Secondary outcome measures
Viremia

Side effects data

From 2012 Phase 3 trial • 552 Patients • NCT01466387
4%
Headache
2%
Injection site pain
2%
Influenza like illness
1%
Nasopharyngitis
100%
80%
60%
40%
20%
0%
Study treatment Arm
MenACWY-CRM197 (Combined)
JE+Rabies+MenACWY-CRM197
TF+YF+MenACWY-CRM197
JE+Rabies
Rabies
TF+YF

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Fractional dose (Group 3)Experimental Treatment1 Intervention
Yellow Fever vaccine 1/10th standard dose, 0.05mL.
Group II: Fractional dose (Group 2)Experimental Treatment1 Intervention
Yellow Fever vaccine 1/5th standard dose, 0.1mL.
Group III: Standard Dose (Group 1)Active Control1 Intervention
Yellow Fever vaccine standard dose, 0.5mL.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Yellow Fever Vaccine
2016
Completed Phase 4
~1490

Find a Location

Who is running the clinical trial?

US Army Medical Research Institute of Infectious DiseasesLead Sponsor
13 Previous Clinical Trials
1,300 Total Patients Enrolled
Phillip R Pittman, M.D., M.P.H.Principal InvestigatorUS Army Medical Research Institute of Infectious Diseases

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Study of the Safety and Immunogenicity of Reduced Doses of the US Yellow Fever Vaccine
2021. "Study of the Safety and Immunogenicity of Reduced Doses of the US Yellow Fever Vaccine". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05374317.
~23 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top